Reagila 1.5 mg hard capsules
Sponsors
Gedeon Richter Plc., Aalborg University Hospital, Medizinische Universitaet Innsbruck
Conditions
Adolescent Patients (13 to 17 years of age) with SchizophreniaAdolescent patient (13-17 years of age) with SchizophreniaDepressive episode in bipolar disorderschizophrenia
Phase 3
2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia
RecruitingCTIS2024-513222-30-00
Start: 2020-02-20Target: 39Updated: 2026-01-16
A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 years of age) with Schizophrenia
RecruitingCTIS2024-513194-44-00
Start: 2021-12-14Target: 42Updated: 2026-01-16
Phase 4
Lithium versus cariprazine in the acute phase treatment of bipolar depression: a pragmatic head-to-head open, randomized multicenter study. The 9th study of the Danish University Antidepressant Group (DUAG 9)
RecruitingCTIS2024-517170-20-01
Start: 2022-12-13Target: 122Updated: 2024-10-02
An open label signal detection study to evaluate the effects of cariprazine on cognitive functioning in patients with schizophrenia in need of adjustment of oral antipsychotic treatment
RecruitingCTIS2024-518042-24-00
Start: 2021-03-21Target: 20Updated: 2024-10-29